DOCSLIB.ORG

Octanol / Water Partitioning Coefficient Logp and Clogp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Octanol / Water Partitioning Coefficient Logp and Clogp Lipid solubility and the brain uptake of compounds • Higher the Kow, the greater the brain uptake • Specific carriers can facilitate brain uptake (glucose, lucine, dopa) • Binding to plasma proteins can reduce uptake (phenytoin) Octanol / Water Partitioning Coefficient logP and ClogP http://www.biobyte.com/ • The logP is an important physicochemical parameter for oral absorption • Measure for the lipophilicity of a compound. • ClogP is the calculated log octanol/water partition coefficient, – It relates to solubility and influences the ability of a compound to permeate cell membranes – Too hydrophilic compounds (negative logP) cannot permeate membranes – Too lipophilic compounds (high logP) are insoluble, poorly permeate through membranes (get stuck in the lipophilic bilayer). 1 Predicting Favorable ADME in Drug Development - Lipinski’s Rule of Five A rule of thumb to evaluate: • If a chemical compound with a Lipinski's rule: An orally active drug has no more than one pharmacological /biological activity violation of the following : has properties that may make it a 1. No more than 5 hydrogen bond donors (N or O with >1 H likely orally active drug. atom) • Rule formulated by Chris Lipinski in 2. Not more than 10 hydrogen bond acceptors (N or O atoms) 1997, based on the observation that most medication drugs are relatively 3. A molecular mass < 500 daltons small and lipophilic molecules 4. An octanol-water partition coefficient (log P) < 5 * As with all ‘rules’, many exceptions! Predicts that poor absorption and permeability of potential drug candidates will occur if: 1) Number of H-bond donors > 5 2) Number of H-bond acceptors > 10 3) Molecular Weight > 500 4) ClogP > 5 Lipinski’s rule does not predict if a compound is pharmacologically active. • Rule is important to keep in mind during drug discovery when a lead structure is optimized step-wise to increase the activity and selectivity. • Candidate drugs that conform to the RO5 tend to have lower attrition rates during clinical trials Drug Metabolism / Biotransformation Learning objectives • Distinguish the differences between Phase I and Phase II reactions • Recognize the enzymes involved in these processes and that various factors (age, genetic predisposition/polymorphisms, co-exposure to other drugs, diet, illness) may affect these processes • Be familiar with at least one example of one of the following types of Phase I biotransformation reactions: Oxidation, Reduction, Hydrolysis. The same goes for the following types of Phase II biotransformation reactions: Conjugation with glucuronide, glutathione, sulfate. • Recognize that one of the possible consequences of biotransformation is the conversion of prodrugs to active drug, or active drug to reactive intermediates, and that depending upon their chemical nature, these intermediates can modify molecular targets through different mechanisms 2 Drug Metabolizing Enzyme System Phase I and Phase II Biotransformation • Phase I metabolism – ‘Functionalization’ • Addition or exposing of a reactive functional group such as -OH, -SH, -NH2 or –COOH – In general, Phase I metabolism prepares the xenobiotic for subsequent Phase II reactions • Phase II Reactions – Enzymatic reactions that conjugate large water- soluble, charged (polar) biomolecules to xenobiotics The Truck-Hitch-Trailer Analogy to Xenobiotic Biotransformation Phase 2 enzymes Phase 1 enzymes conjugate (transfer) Foreign Chemical add or expose a endogenous molecules* (xenobiotic) functional group to the functional group •lipophilic HITCH TRAILER •not charged Phase 1 enzymes add or •not lipophilic •not water soluble expose a functional group •usually not reactive •still lipophilic •water soluble products •poorly excretable •possibly reactive •Excretable •poorly water soluble •catalyzed by transferases •poorly excretable •catalyzed by P450s * sugars, amino acids, sulfates, acetyl groups 3 Biotransformation Enzyme-Containing Cells in Various Organs Organ Cell(s) . Liver Parenchymal cells (hepatocytes) Kidney Proximal tubular cells (S3 segment) Lung Clara cells, Type II alveolar cells Intestine Mucosa lining cells Skin Epithelial cells Testes Seminiferous tubules, Sertoli cells Mixed Function Oxidase System (MFO) (Phase I Metabolism) MFOs Contain: • Cyt. P450, • 2 flavoproteins (P450 reductases), • Cytochrome b5 4 CYP families in humans Humans have 57 genes and more than 59 pseudogenes divided among: • 18 families of cytochrome P450 genes • 43 subfamilies Function Members Names Family CYP1 drug and steroid (especially estrogen) metabolism 3 subfamilies, 3 genes, 1 pseudogene CYP1A1, CYP1A2, CYP1B1 CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2 drug and steroid metabolism 13 subfamilies, 16 genes, 16 pseudogenes CYP2D6, CYP2E1, CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP2W1 CYP3 drug and steroid (including testosterone) metabolism 1 subfamily, 4 genes, 2 pseudogenes CYP3A4, CYP3A5, CYP3A7, CYP3A43 CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4 arachidonic acid or fatty acid metabolism 6 subfamilies, 11 genes, 10 pseudogenes CYP4F22, CYP4V2, CYP4X1, CYP4Z1 CYP5 thromboxane A2 synthase 1 subfamily, 1 gene CYP5A1 CYP7 bile acid biosynthesis 7-alpha hydroxylase of steroid nucleus 2 subfamilies, 2 genes CYP7A1, CYP7B1 CYP8 varied 2 subfamilies, 2 genes CYP8A1 (prostacyclin synthase), CYP8B1 (bile acid biosynthesis) CYP11 steroid biosynthesis 2 subfamilies, 3 genes CYP11A1, CYP11B1, CYP11B2 CYP17 steroid biosynthesis, 17-alpha hydroxylase 1 subfamily, 1 gene CYP17A1 CYP19 steroid biosynthesis: aromatase synthesizes estrogen 1 subfamily, 1 gene CYP19A1 CYP20 unknown function 1 subfamily, 1 gene CYP20A1 CYP21 steroid biosynthesis 2 subfamilies, 2 genes, 1 pseudogene CYP21A2 CYP24 vitamin D degradation 1 subfamily, 1 gene CYP24A1 CYP26 retinoic acid hydroxylase 3 subfamilies, 3 genes CYP26A1, CYP26B1, CYP26C1 CYP27A1 (bile acid biosynthesis), CYP27B1 (vitamin D3 1-alpha hydroxylase, activates CYP27 varied 3 subfamilies, 3 genes vitamin D3), CYP27C1 (unknown function) CYP39 7-alpha hydroxylation of 24-hydroxycholesterol 1 subfamily, 1 gene CYP39A1 CYP46 cholesterol 24-hydroxylase 1 subfamily, 1 gene CYP46A1 CYP51 cholesterol biosynthesis 1 subfamily, 1 gene, 3 pseudogenes CYP51A1 (lanosterol 14-alpha demethylase) Cytochrome P450 Characteristics • Broad substrate specificity - – Most drug metabolizing CYPs are promiscuous re: substrate, – but some CYPs are highly specific to substrate, e.g., Cyp 19 (aromatase w/ testosterone substrate). – CYP enzyme levels induced by exposure to xenobiotics • Broad substrate specficity = Low catalytic efficiency (Kcat). – Drugs in general have t1/2 of 3 – 30 hrs, while endogenous substrates are much shorter (sec or min) – reflects lower Kcat of drug CYPs. • Broad substrate specificity of many CYPs accounts for much of reason for drug – drug interactions. – Multiple drugs may compete for binding site, altering metabolism of one or more of the drugs, thereby increasing t1/2 and plasma levels (Dixogin example). 5 Cytochrome P450’s • Limted number of CYPs (15) in families 1 – 3 are mostly responsible for drug metabolism. • In humans, 12 CYPs in particular important: CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5. • The most active in drug metabolism are the 2C, 2D, and 3A subfamiles, with CYP3A4 involved in metabolism of ~50% of clinically used drugs. Cytochrome P450 Substrate Binding • P450s possess active HEME group: • 2 types of substrate binding to P450 – Type 1 Binding: The substrate binds to a protein moiety near the active site. This brings the substrate within the region of the catalytic activity of the Heme-Fe. Fe in Low Spin – Type II Binding: The substrate binds directly to the Heme-Fe. Fe in High Spin Can determine whether Type I or Type II binding spectrophotometrically -Type I binding of Cyt. P450 to the substrate gives a characteristic AMAX of around 390nm. -Type II binding of Cyt. P450 to the substrate gives a characteristic AMAX of around 420nm. 6 Systems Involved in Phase II Metabolism Four primary enzymes: 1. Glucuronosyltransferase—glucuronic acid 2. Sulfotransferase—sulfate 3. Glutathione-S-transferase—glutathione (GSH) 4. Acetyltransferase—acetyl • enzymes are, for the most part, in the cytosol of cells • In all cases (except GSH) – requires conjugate activated to an Electrophilic Activated Donor Phase II Enzymes: Examples Glucuronidation and Sulfation of a Hydroxyl Group 7 UDP Conjugation - Phenytoin • Phenytoin – Common antiepileptic • Marketed as Phenytek, Dilantin • Insoluble in water • Stabilizes inactive state of voltage-gated Na channels • Induces CYP3A4, 2C19 • Interactions: • Coumarin and Warfarin increase serum phenytoin levels and prolong the serum half-life of phenytoin by inhibiting its metabolism • Pharmacokinetics – can be saturable, leading to highly variable plasma levels across minor dose changes Bioactivation and UDP Conjugation: Irinotecan • Irinotecan – cancer drug (mostly colon cancer). • Topoisomerase 1 inhibitor – leads to inhibition of DNA replication • Administered as ProDrug • Carboxyesterase activates to active drug (SN-38) 8 Gilbert’s Syndrome Drug – Polymorphism interaction • Generally benign condition present in ~10% of pop’n. • Diagnosed clinically because circulating bilirubin levels are 60 – 70% elevated. • Most common genetic polymorph associated with Gilbert’s is mutation in UGT1A1 gene promoter, leading to reduced expression of UGT1A1. • If drug undergoes Phase II with UGT1A1, it will compete with bilirubin metabolism conjugation,
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Transcriptomic Characterization of Fibrolamellar Hepatocellular
    Transcriptomic characterization of fibrolamellar PNAS PLUS hepatocellular carcinoma Elana P. Simona, Catherine A. Freijeb, Benjamin A. Farbera,c, Gadi Lalazara, David G. Darcya,c, Joshua N. Honeymana,c, Rachel Chiaroni-Clarkea, Brian D. Dilld, Henrik Molinad, Umesh K. Bhanote, Michael P. La Quagliac, Brad R. Rosenbergb,f, and Sanford M. Simona,1 aLaboratory of Cellular Biophysics, The Rockefeller University, New York, NY 10065; bPresidential Fellows Laboratory, The Rockefeller University, New York, NY 10065; cDivision of Pediatric Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; dProteomics Resource Center, The Rockefeller University, New York, NY 10065; ePathology Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; and fJohn C. Whitehead Presidential Fellows Program, The Rockefeller University, New York, NY 10065 Edited by Susan S. Taylor, University of California, San Diego, La Jolla, CA, and approved September 22, 2015 (received for review December 29, 2014) Fibrolamellar hepatocellular carcinoma (FLHCC) tumors all carry a exon of DNAJB1 and all but the first exon of PRKACA. This deletion of ∼400 kb in chromosome 19, resulting in a fusion of the produced a chimeric RNA transcript and a translated chimeric genes for the heat shock protein, DNAJ (Hsp40) homolog, subfam- protein that retains the full catalytic activity of wild-type PKA. ily B, member 1, DNAJB1, and the catalytic subunit of protein ki- This chimeric protein was found in 15 of 15 FLHCC patients nase A, PRKACA. The resulting chimeric transcript produces a (21) in the absence of any other recurrent mutations in the DNA fusion protein that retains kinase activity.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Colorectal Cancer and Omega Hydroxylases
    1 The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance Abdo Alnabulsi1,2, Rebecca Swan1, Beatriz Cash2, Ayham Alnabulsi2, Graeme I Murray1 1Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB25, 2ZD, UK. 2Vertebrate Antibodies, Zoology Building, Tillydrone Avenue, Aberdeen, AB24 2TZ, UK. Address correspondence to: Professor Graeme I Murray Email [email protected] Phone: +44(0)1224 553794 Fax: +44(0)1224 663002 Running title: omega hydroxylases and colorectal cancer 2 Abstract Background: Colorectal cancer is a common malignancy and one of the leading causes of cancer related deaths. The metabolism of omega fatty acids has been implicated in tumour growth and metastasis. Methods: This study has characterised the expression of omega fatty acid metabolising enzymes CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 using monoclonal antibodies we have developed. Immunohistochemistry was performed on a tissue microarray containing 650 primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosa. Results: The differential expression of CYP4A11 and CYP4F11 showed a strong association with survival in both the whole patient cohort (HR=1.203, 95% CI=1.092-1.324, χ2=14.968, p=0.001) and in mismatch repair proficient tumours (HR=1.276, 95% CI=1.095-1.488, χ2=9.988, p=0.007). Multivariate analysis revealed that the differential expression of CYP4A11 and CYP4F11 was independently prognostic in both the whole patient cohort (p = 0.019) and in mismatch repair proficient tumours (p=0.046). Conclusions: A significant and independent association has been identified between overall survival and the differential expression of CYP4A11 and CYP4F11 in the whole patient cohort and in mismatch repair proficient tumours.
    [Show full text]
  • Effect of Genetic Variability in the CYP4F2, CYP4F11 and CYP4F12 Genes on Liver Mrna Levels and Warfarin Response
    Effect of genetic variability in the CYP4F2, CYP4F11 and CYP4F12 genes on liver mRNA levels and warfarin response J. Eunice Zhang1, Kathrin Klein2, Andrea L. Jorgensen3, Ben Francis3, Ana Alfirevic1, Stephane Bourgeois4, Panagiotis Deloukas4,5,6, Ulrich M. Zanger2 and Munir Pirmohamed1* 1Wolfson Centre for Personalized Medicine, Department of Molecular & Clinical Pharmacology, The University of Liverpool, UK 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany. 3Department of Biostatistics, The University of Liverpool, UK 4William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK 5Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. 6Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia. Correspondence: Professor Sir Munir Pirmohamed Wolfson Centre for Personalised Medicine Department of Molecular & Clinical Pharmacology Block A: Waterhouse Buildings The University of Liverpool 1-5 Brownlow Street L69 3GL, UK [email protected] Running Title: Genotype-phenotype assessment of CYP4F12-CYP4F2-CYP4F11 region Keywords: warfarin, pharmacogenetics, mRNA expression, CYP4F2, CYP4F11, CYP4F12 1 Abstract Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K oxidase, affect stable warfarin dose requirements and time to therapeutic INR. CYP4F2 is part of the CYP4F gene cluster, which is highly polymorphic and exhibits a high degree of linkage disequilibrium, making it difficult to define causal variants. Our objective was to examine the effect of genetic variability in the CYP4F gene cluster on expression of the individual CYP4F genes and warfarin response. mRNA levels of the CYP4F gene cluster were quantified in human liver samples (n=149) obtained from a well characterized liver bank and fine mapping of the CYP4F gene cluster encompassing CYP4F2, CYP4F11 and CYP4F12 was performed.
    [Show full text]
  • Screening 20-Hete Inhibitors in Microsomal Incubates
    SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS by Chenxiao Tang Bachelor of Science, Capital Medical University, 2014 Submitted to the Graduate Faculty of School of Pharmacy in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2016 Copyright © by Chenxiao Tang 2016 ii SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS Chenxiao Tang, B.S. University of Pittsburgh, 2016 20-hydroxyeicosatetraenoic acid (20-HETE) is a metabolite of arachidonic acid (AA) formed by cytochrome P450 (CYP) 4A11 and CYP4F2 in humans, with potent microvascular constriction activity. Inhibition of 20-HETE formation is neuroprotective in subarachnoid hemorrhage, cardiac arrest and thromboembolic stroke preclinical models. These findings suggest that inhibition of 20-HETE formation is a potential therapeutic strategy for neuroprotection after brain injury. At this point, a clinically relevant 20-HETE inhibitor is not available to be evaluated as a therapeutic intervention. Our goal is to identify a selective, metabolically stable, and potent 20-HETE inhibitor. Test compounds were obtained either via virtual screening against a CYP4F2 homology model or from scaffold hopping from structures of known inhibitors. Four different types of microsomes including human liver microsome (HLM), recombinant CYP4F2 (rCYP4F2), rat liver microsome (RLM) and rat kidney microsome (RKM) were used. AA was incubated in microsomes with/without compound for 20 min. 20-HETE formation rate was quantified using a validated UPLC-MS/MS assay and normalized by vehicle control group. Other eicosanoids including 15-, 12-HETEs, epoxyeicosatrienoic acids (EETs), iii and dihydroxyeicosatrienoic acids (DiHETs) were monitored simultaneously.
    [Show full text]
  • Early Pregnancy Maternal Progesterone Administration Alters Pituitary and Testis Function and Steroid Profile in Male Fetuses
    www.nature.com/scientificreports OPEN Early pregnancy maternal progesterone administration alters pituitary and testis function and steroid profle in male fetuses Katarzyna J. Siemienowicz1,2*, Yili Wang1, Magda Marečková1, Junko Nio‑Kobayashi1,3, Paul A. Fowler4, Mick T. Rae2 & W. Colin Duncan1 Maternal exposure to increased steroid hormones, including estrogens, androgens or glucocorticoids during pregnancy results in chronic conditions in ofspring that manifest in adulthood. Little is known about efects of progesterone administration in early pregnancy on fetal development. We hypothesised that maternal early pregnancy progesterone supplementation would increase fetal progesterone, afect progesterone target tissues in the developing fetal reproductive system and be metabolised to other bioactive steroids in the fetus. We investigated the efects of progesterone treatment during early pregnancy on maternal and fetal plasma progesterone concentrations, transcript abundance in the fetal pituitary and testes and circulating steroids, at day 75 gestation, using a clinically realistic ovine model. Endogenous progesterone concentrations were lower in male than female fetuses. Maternal progesterone administration increased male, but not female, fetal progesterone concentrations, also increasing circulating 11‑dehydrocorticosterone in male fetuses. Maternal progesterone administration altered fetal pituitary and testicular function in ovine male fetuses. This suggests that there may be fetal sex specifc efects of the use of progesterone in early pregnancy, and highlights that progesterone supplementation should be used only when there is clear evidence of efcacy and for as limited time as necessary. Fetal exposure to sex steroids has critical roles in sexual diferentiation and the programming of health and dis- ease in later life1. Exposure to endocrine disrupting compounds is linked to disease development in ofspring2.
    [Show full text]
  • The Differential Expression of Omega-3 and Omega-6 Fatty Acid Metabolising Enzymes in Colorectal Cancer and Its Prognostic Significance
    FULL PAPER British Journal of Cancer (2017) 116, 1612–1620 | doi: 10.1038/bjc.2017.135 Keywords: biomarker; colorectal cancer; cytochrome P450; omega fatty acid; prognosis The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance Abdo Alnabulsi1,2, Rebecca Swan1, Beatriz Cash2, Ayham Alnabulsi2 and Graeme I Murray*,1 1Department of Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25, 2ZD, UK and 2Vertebrate Antibodies, Zoology Building, Tillydrone Avenue, Aberdeen AB24 2TZ, UK Background: Colorectal cancer is a common malignancy and one of the leading causes of cancer-related deaths. The metabolism of omega fatty acids has been implicated in tumour growth and metastasis. Methods: This study has characterised the expression of omega fatty acid metabolising enzymes CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 using monoclonal antibodies we have developed. Immunohistochemistry was performed on a tissue microarray containing 650 primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosa. Results: The differential expression of CYP4A11 and CYP4F11 showed a strong association with survival in both the whole patient cohort (hazard ratio (HR) ¼ 1.203, 95% CI ¼ 1.092–1.324, w2 ¼ 14.968, P ¼ 0.001) and in mismatch repair-proficient tumours (HR ¼ 1.276, 95% CI ¼ 1.095–1.488, w2 ¼ 9.988, P ¼ 0.007). Multivariate analysis revealed that the differential expression of CYP4A11 and CYP4F11 was independently prognostic in both the whole patient cohort (P ¼ 0.019) and in mismatch repair proficient tumours (P ¼ 0.046). Conclusions: A significant and independent association has been identified between overall survival and the differential expression of CYP4A11 and CYP4F11 in the whole patient cohort and in mismatch repair-proficient tumours.
    [Show full text]
  • Rapid Birth–Death Evolution Specific to Xenobiotic Cytochrome P450 Genes in Vertebrates
    Rapid Birth–Death Evolution Specific to Xenobiotic Cytochrome P450 Genes in Vertebrates James H. Thomas* Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America Genes vary greatly in their long-term phylogenetic stability and there exists no general explanation for these differences. The cytochrome P450 (CYP450) gene superfamily is well suited to investigating this problem because it is large and well studied, and it includes both stable and unstable genes. CYP450 genes encode oxidase enzymes that function in metabolism of endogenous small molecules and in detoxification of xenobiotic compounds. Both types of enzymes have been intensively studied. My analysis of ten nearly complete vertebrate genomes indicates that each genome contains 50–80 CYP450 genes, which are about evenly divided between phylogenetically stable and unstable genes. The stable genes are characterized by few or no gene duplications or losses in species ranging from bony fish to mammals, whereas unstable genes are characterized by frequent gene duplications and losses (birth–death evolution) even among closely related species. All of the CYP450 genes that encode enzymes with known endogenous substrates are phylogenetically stable. In contrast, most of the unstable genes encode enzymes that function as xenobiotic detoxifiers. Nearly all unstable CYP450 genes in the mouse and human genomes reside in a few dense gene clusters, forming unstable gene islands that arose by recurrent local gene duplication. Evidence for positive selection in amino acid sequence is restricted to these unstable CYP450 genes, and sites of selection are associated with substrate-binding regions in the protein structure. These results can be explained by a general model in which phylogenetically stable genes have core functions in development and physiology, whereas unstable genes have accessory functions associated with unstable environmental interactions such as toxin and pathogen exposure.
    [Show full text]
  • CYP4F11 Monoclonal Antibody, Clone F21 P6 F5
    CYP4F11 monoclonal antibody, enzymes. The cytochrome P450 proteins are clone F21 P6 F5 monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of Catalog Number: MAB1861 cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Regulatory Status: For research use only (RUO) Another member of this family, CYP4F2, is approximately 16 kb away. Alternatively spliced Product Description: Mouse monoclonal antibody transcript variants encoding the same protein have been raised against synthetic peptide of CYP4F11. found for this gene. [provided by RefSeq] Clone Name: F21 P6 F5 References: 1. Cytochrome p450 profile of colorectal cancer: Immunogen: A synthetic peptide corresponding to identification of markers of prognosis. C-terminus of human CYP4F11. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, Murray GI. Clin Cancer Res. Host: Mouse 2005 May 15;11(10):3758-65. 2. Expression and characterization of human Reactivity: Human cytochrome P450 4F11: Putative role in the metabolism Applications: ELISA, IHC-P, WB-Ti of therapeutic drugs and eicosanoids. Kalsotra A, (See our web site product page for detailed applications Turman CM, Kikuta Y, Strobel HW. Toxicol Appl information) Pharmacol. 2004 Sep 15;199(3):295-304. 3. A novel human cytochrome P450 4F isoform Protocols: See our web site at (CYP4F11): cDNA cloning, expression, and genomic http://www.abnova.com/support/protocols.asp or product structural characterization. Cui X, Nelson DR, Strobel page for detailed protocols HW. Genomics. 2000 Sep 1;68(2):161-6. Form: Liquid Isotype: IgG1 Recommend Usage: Western Blot (1-2 ug/mL) Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) (1-5 ug/mL) The optimal working dilution should be determined by the end user.
    [Show full text]
  • Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers Diane Downie,1Morag C.E
    Imaging, Diagnosis, Prognosis Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers Diane Downie,1Morag C.E. McFadyen,1Patrick H. Rooney,1, 3 Margaret E. Cruickshank,2 David E. Parkin,2 Iain D. Miller,1Colin Telfer,3 William T. Melvin,3 and Graeme I. Murray1 Abstract Purpose: The cytochromes P450 are a multigene family of enzymes with a central role in the oxidative metabolism of a wide range of xenobiotics, including anticancer drugs and biologically active endogenous compounds. The purpose of this study was to define the cytochrome P450 profile of ovarian cancer and identify novel therapeutic targets and establish the prognostic signif- icance of expression of individualcytochrome P450s in this type of cancer. Experimental Design: Immunohistochemistry for a panelof 23 cytochrome P450s and cyto- chrome P450 reductase was done on an ovarian cancer tissue microarray consisting of 99primary epithelialovarian cancers, 22 peritonealmetastasis, and 13 normalovarian samples.The intensity of immunoreactivity in each sample was established by light microscopy. Results: In primary ovarian cancer, several P450s (CYP1B1, CYP2A/2B, CYP2F1, CYP2R1, CYP2U1,CYP3A5, CYP3A7,CYP3A43, CYP4Z1,CYP26A1,and CYP51)were present at a signif- icantlyhigher levelof intensity compared with normalovary. P450 expression was alsodetected in ovarian cancer metastasis and CYP2S1and P450 reductase both showed significantly in- creased expression in metastasis compared with primary ovarian cancer. The presence of low/ negative CYP2A/2B (log rank = 7.06, P = 0.008) or positive CYP4Z1 (log rank = 6.19, P =0.01) immunoreactivity in primary ovarian cancer were each associated with poor prognosis. Both CYP2A/2B and CYP4Z1were also independent markers of prognosis.
    [Show full text]
  • Biodiversity of P-450 Monooxygenase: Cross-Talk
    Cytochrome P450: Oxygen activation and biodiversty 1 Biodiversity of P-450 monooxygenase: Cross-talk between chemistry and biology Heme Fe(II)-CO complex 450 nm, different from those of hemoglobin and other heme proteins 410-420 nm. Cytochrome Pigment of 450 nm Cytochrome P450 CYP3A4…. 2 High Energy: Ultraviolet (UV) Low Energy: Infrared (IR) Soret band 420 nm or g-band Mb Fe(II) ---------- Mb Fe(II) + CO - - - - - - - Visible region Visible bands Q bands a-band, b-band b a 3 H2O/OH- O2 CO Fe(III) Fe(II) Fe(II) Fe(II) Soret band at 420 nm His His His His metHb deoxy Hb Oxy Hb Carbon monoxy Hb metMb deoxy Mb Oxy Mb Carbon monoxy Mb H2O/Substrate O2-Substrate CO Substrate Soret band at 450 nm Fe(III) Fe(II) Fe(II) Fe(II) Cytochrome P450 Cys Cys Cys Cys Active form 4 Monooxygenase Reactions by Cytochromes P450 (CYP) + + RH + O2 + NADPH + H → ROH + H2O + NADP RH: Hydrophobic (lipophilic) compounds, organic compounds, insoluble in water ROH: Less hydrophobic and slightly soluble in water. Drug metabolism in liver ROH + GST → R-GS GST: glutathione S-transferase ROH + UGT → R-UG UGT: glucuronosyltransferaseGlucuronic acid Insoluble compounds are converted into highly hydrophilic (water soluble) compounds. 5 Drug metabolism at liver: Sleeping pill, pain killer (Narcotic), carcinogen etc. Synthesis of steroid hormones (steroidgenesis) at adrenal cortex, brain, kidney, intestine, lung, Animal (Mammalian, Fish, Bird, Insect), Plants, Fungi, Bacteria 6 NSAID: non-steroid anti-inflammatory drug 7 8 9 10 11 Cytochrome P450: Cysteine-S binding to Fe(II) heme is important for activation of O2.
    [Show full text]